NCT01387230View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

PHASE3CompletedINTERVENTIONAL

Enrollment

206

Participants

Timeline

Start Date

July 1, 2011

Primary Completion Date

February 1, 2012

Study Completion Date

February 13, 2012

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK573719

62.5 mcg

DRUG

GSK573719

125mcg

OTHER

Placebo

Placebo

Trial Locations (27)

10117

GSK Investigational Site, Berlin

10367

GSK Investigational Site, Berlin

10717

GSK Investigational Site, Berlin

13086

GSK Investigational Site, Berlin

13187

GSK Investigational Site, Berlin

23552

GSK Investigational Site, Lübeck

28844

GSK Investigational Site, Weyhe-Leeste

29303

GSK Investigational Site, Spartanburg

29379

GSK Investigational Site, Union

29640

GSK Investigational Site, Easley

30173

GSK Investigational Site, Hanover

34121

GSK Investigational Site, Kassel

42651

GSK Investigational Site, Solingen

47574

GSK Investigational Site, Goch

51069

GSK Investigational Site, Cologne

56068

GSK Investigational Site, Koblenz

60389

GSK Investigational Site, Frankfurt am Main

63571

GSK Investigational Site, Gelnhausen

70584

GSK Investigational Site, Sunset

04109

GSK Investigational Site, Leipzg

04103

GSK Investigational Site, Leipzig

06682

GSK Investigational Site, Teuchern

319-1113

GSK Investigational Site, Ibaraki

762-0031

GSK Investigational Site, Kagawa

612-0026

GSK Investigational Site, Kyoto

530-0001

GSK Investigational Site, Osaka

103-0027

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01387230 - Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD | Biotech Hunter | Biotech Hunter